tradmap

INDV Earnings Indivior Pharmaceuticals, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$1 $0 $2 $0 2023 2024 2025
EPS
Revenue (annual)
$0 $620M $1B 2022 2023 2024 2025
Revenue
Net income (annual)
-$126M $42M $210M $0 2022 2023 2024 2025
Net income

Quarterly results

Diluted EPS (quarterly)
-$0 $1 $2 $0 Q4 '22 Q1 '24 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q1 '26 Q2 '26
EPS
Revenue (quarterly)
$0 $179M $358M Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26
Revenue
Net income (quarterly)
-$97M $3M $102M $0 Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26
Net income

Reported EPS history

1–12 of 12
Q2 20262026-06-301.672026-08-0310-Q
Q1 20262026-03-310.692026-04-3010-Q
FY 20252025-12-311.642026-02-2610-K
Q3 20252025-09-300.852025-10-3010-Q
Q2 20262025-06-300.522026-08-0310-Q
Q1 20262025-03-310.382026-04-3010-Q
FY 20252024-12-310.052026-02-2610-K
Q3 20252024-09-30-0.112025-10-3010-Q
Q2 20252024-06-30-0.272025-07-3110-Q
Q1 20252024-03-310.452025-05-0110-Q
FY 20252023-12-31-0.922026-02-2610-K
Q3 20252022-12-31-0.302025-10-3010-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.